Tactile Systems Technology, Inc. (TCMD) - Stock Analysis
Last updated: Mar 9, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Q4 beat with 21% revenue growth, margin expansion, deleveraging (term loan repaid), and a buyback plus positive clinical data for Flexitouch have produced a sharp breakout (~10% over 21 days, 15% above the 21-day SMA); near-term upside is supported by strong fundamentals and follow-through on payer/volume metrics.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong liquidity ⢠High gross margin ⢠Elevated operating costs TCMD has a very healthy balance sheet, high gross margins and strong FCF/ROIC but steep SG&A compresses net margins and the stock trades at a premium.
Price Behavior
Key Price Behavior Insights: ⢠Modest upside ⢠Defended support ⢠Sharp reversal risk Support Level: $28.6â$28.8 Resistance Level: $30.0â$30.7 Modestly up over the last month but rangeâbound with buyers defending ~$28.6â28.8, resistance near $30.0â30.7 and a oneâday spike to $33.05 on 2026â02â18 that quickly reversed, implying muted momentum and newsâdriven volatility
Sentiment & News
Key News Insights: ⢠Revenue acceleration ⢠Balance-sheet repair ⢠Strategic acquisition Tactile Systems beat Q4 expectations with 21% revenue growth, margin expansion, debt reduction, a LymphaTech acquisition and buybacks that spurred analyst upgrades, a sharp stock jump and bullish technicals.
AI Summary
TCMD has transitioned from a growth-at-all-costs clinical rollâout to a cash-generating, margin-expandable lymphedema commercial platform, making repeatable free cash flow and SG&A leverage the primary drivers of upside rather than early-stage market creation. Investors should track quarterly FCF consistency, DSO/receivables trends, and near-term payer policy (LCDâNCD) cadenceâfavorable SG&A compression and policy wins would materially re-rate the stock while collections or reimbursement setbacks would quickly compress multiples.
Description
Tactile Systems Technology, Inc. is a U.S.-based medical device company that produces and markets noninvasive therapies for chronic conditions. Its product portfolio includes pneumatic compression systems for lymphedema and other venous disorders and a portable chest wall oscillation device for managing retained pulmonary secretions. The company was incorporated in 1995 and is headquartered in Minneapolis, Minnesota.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Feb 19 | Feb 26 | TCMD | Tactile Systems Technology, Inc. | Q4 beat with 21% revenue growth, margin expansion, deleveraging (term loan repaid), and a buyback plus positive clinical data for Flexitouch have produced a sharp breakout (~10% over 21 days, 15% above the 21-day SMA); near-term upside is supported by strong fundamentals and follow-through on payer/volume metrics. | Closed | +5.9% |